I am a healthcare professional
If you are a healthcare professional looking to find out more about heavy menstrual bleeding and contraception, please click below.
If you are not a healthcare professional and you want to learn about contraception please click below.
If you are not a healthcare professional and you want to learn about heavy menstural bleedingplease click below.
HCP

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Bayer logo

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

NICE: HMB standard update

06 November 2019

NICE prepares for updating the NICE Quality Standard on HMB, due for publication in 2020.

In preparation for a consultation on the draft quality standard, due to launch on 19 November 2019 and with an anticipated updated standard published in June 2020, NICE has published a topic overview on heavy menstrual bleeding. Alongside the existing core elements of the quality standard, NICE invited stakeholders to identify a maximum of five key areas for quality improvement. As these may feature in the quality standard, it is already worth keeping front-of-mind when engaging on HMB treatment.

Bayer has focus on the following three key areas:

  • Provision of information for women about HMB and treatments;
  • Management of HMB for women with no identified pathology; and
  • Recognition of HMB as having a major impact on a women’s quality of life and ensuring that any intervention aims to improve this rather than focusing on blood loss.

For more information, please refer to the NICE Quality Standard Topic Overview on HMB

Recommendations

Online learning

Read more

Upcoming webinars

Read more

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Bayer plc Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.

  • PP-PF-WHC-GB-0275 November 2019

Copyright © 2019,
Bayer plc

This website is intended for UK healthcare professionals only. Women’s Health Matters is organised and funded by Bayer and contains promotional content.

Prescribing Information (PI) can be found via the links below:
Mirena® (52 mg intrauterine delivery system Levonorgestrel)
Kyleena® (19.5 mg intrauterine delivery system Levonorgestrel)
Jaydess® (13.5 mg intrauterine delivery system Levonorgestrel)
Qlaira® (estradiol valerate/dienogest)
Microgynon® (levonorgestrel/ethinylestradiol)

Page last modified Tue, 06/02/2020 - 05:20

Bayer logo